gms | German Medical Science

72. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC)
Joint Meeting mit der Polnischen Gesellschaft für Neurochirurgie

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

06.06. - 09.06.2021

Artikel

Artikel empfehlen

Direct oral anticoagulants vs. low-molecular-weight heparin for pulmonary embolism in glioblastoma

Direkte orale Antikoagulantien vs. niedermolekulares Heparin zur Behandlung der Lungenembolie im Glioblastom

Meeting Abstract

Suche in Medline nach

  • presenting/speaker Daniel Dubinski - University Hospital Frankfurt, Neurosurgery, Frankfurt am Main, Deutschland
  • Sae-Yeon Won - University Hospital Frankfurt, Neurosurgery, Frankfurt am Main, Deutschland
  • Max Dosch - University Hospital Frankfurt, Neurosurgery, Frankfurt am Main, Deutschland
  • Martin Voß - University Hospital Frankfurt, Dr. Senckenberg Institute of Neurooncology, Frankfurt am Main, Deutschland
  • Fee Keil - University Hospital Frankfurt, Neuroradiology, Frankfurt am Main, Deutschland
  • Bedjan Behmanesh - University Hospital Frankfurt, Neurosurgery, Frankfurt am Main, Deutschland
  • Peter Baumgarten - University Hospital Frankfurt, Neurosurgery, Frankfurt am Main, Deutschland
  • Volker Seifert - University Hospital Frankfurt, Neurosurgery, Frankfurt am Main, Deutschland
  • Thomas Freiman - University Hospital Frankfurt, Neurosurgery, Frankfurt am Main, Deutschland
  • Florian Gessler - University Hospital Frankfurt, Neurosurgery, Frankfurt am Main, Deutschland

Deutsche Gesellschaft für Neurochirurgie. 72. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Polnischen Gesellschaft für Neurochirurgie. sine loco [digital], 06.-09.06.2021. Düsseldorf: German Medical Science GMS Publishing House; 2021. DocV110

doi: 10.3205/21dgnc105, urn:nbn:de:0183-21dgnc1052

Veröffentlicht: 4. Juni 2021

© 2021 Dubinski et al.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe http://creativecommons.org/licenses/by/4.0/.

Gliederung

Text

Objective: Glioblastoma (GBM) is a cancer type with high thrombogenic potential and GBM patients are therefore at a particularly high risk for thrombotic events. To date only limited data on anticoagulation management after pulmonary embolism (PE) in GBM is available and the use of DOACs remain off-labe.l

Methods: A retrospective comparative cohort analysis of patients with GBM and postoperative, thoracic CT-scan confirmed, PE was performed. Clinical course, follow-up at 6 and 12 months and overall survival (OS) were evaluated using medical charts and neuroradiological data.

Results: Out of 584 GBM patients, 8% suffered from postoperative PE. Out of theses, 30% received DOACs and 70% LMWH for therapeutic anticoagulation. There was no significant difference in major intracranial hemorrhage (ICH), re-thrombosis or re-embolism between the two cohorts. Although statistically non-significant, a tendency to reduced mRS at 6- and 12- months was observed in the LMWH cohort. Furthermore, patients receiving DOACs had a statistical benefit in OS.

Conclusion: In our analysis DOACs showed a favourable safety profile in terms of major ICH, re-thrombosis and re-embolism in GBM patients with postoperative PE. Prospective, randomized trials are urgent to evaluate DOACs for therapeutic anticoagulation in GBM patients with PE.